Pfiz­er, Astel­las clinch ex­pand­ed ap­proval for Xtan­di in ear­li­er line of prostate can­cer

Last year
R&D
Pharma

Q&A with Ju­dith Ng-Cashin, CRO Novotech's chief med­ical of­fi­cer, on 2023 and be­yond

Last year
People

Ab­b­Vie ad­vis­es frus­trat­ed pso­ri­a­sis pa­tients to get ‘Re­al Clear’ in new aware­ness cam­paign

Last year
Pharma
Marketing

Biden taps Van­der­bilt’s Kim­ryn Rath­mell to suc­ceed Bertag­nol­li as the NI­H's can­cer chief

Last year
People
Pharma

Mer­ck notch­es 38th ap­proval for Keytru­da, sev­enth in­di­ca­tion for gas­troin­testi­nal can­cer

Last year
Pharma
FDA+

Astel­las de­tails po­ten­tial rea­son be­hind deaths in rare dis­ease gene ther­a­py tri­al

Last year
R&D
Cell/Gene Tx

CD­MOs in­ves­ti­gate how to sup­port GLP-1 man­u­fac­tur­ing, phar­ma con­sid­ers sup­ply chain di­ver­si­ty: #Jef­feries23

Last year
Manufacturing

Dana­her/Ab­cam deal set to close next month; Cereno's loan; March Bio­sciences to ad­vance its CAR-T in­to PhII

Last year
News Briefing

Lil­ly in­vests $2.5B in new Ger­man site to boost tirzepatide sup­ply, $100M for lo­cal biotechs

Last year
R&D
Manufacturing

Why a pair of health tech star­tups just merged their re­fer­ral and spe­cial­ty care busi­ness­es

Last year
Health Tech

As­traZeneca sub­sidiary to sell its Ban­ga­lore site, to hunt for ex­ter­nal man­u­fac­tur­er 

Last year
Manufacturing

As­traZeneca lands FDA ap­proval for AKT in­hibitor in bio­mark­er-de­fined breast can­cer sub­set

Last year
Pharma
FDA+

Q&A: Can on­colyt­ic virus­es make a come­back? Ex­perts dis­sect clin­i­cal fail­ures and out­line path for­ward

Last year
R&D

De­sign Ther­a­peu­tics hints at ‘strate­gic re­align­ment,’ re­places CEO; Karyopharm co-founder leads AT­P's Nereid

Last year
Peer Review

Mu­sic agency cre­ates par­o­dy ‘Bravu­ra’ drug ad to am­pli­fy its knack for phar­ma mar­ket­ing scores

Last year
Pharma
Marketing

Slew of House De­moc­rats urge FDA, HHS to pre­serve ac­cess to miso­pros­tol, methotrex­ate

Last year
Pharma
FDA+

Pa­tient foun­da­tion ac­cus­es rare dis­ease com­pa­ny Taysha of vi­o­lat­ing li­cens­ing agree­ment

Last year
R&D
Cell/Gene Tx

'Well un­der­way': FDA calls for faster con­fir­ma­to­ry tri­als for ac­cel­er­at­ed ap­provals

Last year
Pharma
FDA+

FDA's Janet Wood­cock to re­tire in ear­ly 2024

Last year
People
FDA+

Klick Health agency adds AI teams to ac­cel­er­ate phar­ma and health­care mar­ket­ing projects

Last year
AI
Pharma

San­doz opens two new fa­cil­i­ties; Gates Foun­da­tion funds nee­dle-free vac­cines; No­var­tis ex­pands Japan­ese site

Last year
Manufacturing

Biotech’s IPO out­look for the rest of the year sours in wake of war, broad­er in­dus­try strug­gles

Last year
Financing
Startups

Spring­Works eyes US fil­ing for MEK in­hibitor af­ter pos­i­tive PhI­Ib da­ta in rare dis­ease

Last year
R&D

Am­gen lines up new AI biotech part­ner in PostEra to de­vel­op small mol­e­cule med­i­cines

Last year
Deals
AI
First page Previous page 243244245246247248249 Next page Last page
A service from the Financial Times